Up-regulation of plasma miRNA-21 and miRNA-422a in postmenopausal osteoporosis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
12
2022
accepted:
06
06
2023
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
Many researchers focused on diverse miRNAs in the progression of osteoporosis in postmenopausal women. This study aimed to evaluate the association between plasma miRNA-21-5p and miRNA-422a with osteoporosis in postmenopausal women. This cross-sectional comparative study was performed on 126 randomly selected postmenopausal women aged 50-65, including 65 osteoporotic and 61 normal-bone mineral density (BMD) women. miRNA-21 and miRNA-422a were identified using qRT-PCR in these women. BMD was evaluated by the dual-energy X-ray absorptiometry method. A binary logistic regression model adjusted for confounders was used to evaluate the associations between plasma miRNAs' expression levels and osteoporosis. The Area Under Curve (AUC) was calculated to differentiate low BMD in the postmenopausal period using Receiver-Operator Characteristic (ROC) curves. miRNA-21 and miRNA-422a were significantly up-regulated in osteoporotic compared to non-osteoporotic postmenopausal women. The expression levels of miRNA-21 and miRNA-422a indicated a significant reverse correlation with both lumbar spine and femoral neck density. After adjusting the confounders, the likelihood of osteoporosis in the postmenopausal women with under the median plasma levels of miRNA-21 (OR = 0.025; 95% CI: 0.003 to 0.198, p<0.001) and miRNA-422a (OR = 0.037; 95% CI: 0.007 to 0.211, p<0.001) was significantly less than the women with the levels above the median. There were significant inverse correlations between miRNA-21 (p<0.001, r = -0.511) and miRNA-422a (p<0.001, r = -0.682) with BMD-lumbar spine as well as an inverse correlation between miRNA-21(p<0.001, r = -0.374) and miRNA-422a (p<0.001, r = -0.602) with BMD-femoral neck. The AUC (95%CI) for miRNA-21 and miRNA-422a was 0.84 (0.77 to 0.91) and 0.98 (0.96 to 0.99), respectively. ROC analysis illustrated that sensitivity and specificity values were 83.1% and 74%, respectively, for miRNA-21 at the cut-off point of 3.38. Also, at the cut-off point of 2.86, a sensitivity of 94% as well as a specificity of 89% was determined for miRNA-422a. This study indicated that the odds of osteoporosis in postmenopausal women increased with the higher expression of plasma miRNA-21 and miRNA-422a.
Sections du résumé
BACKGROUND
Many researchers focused on diverse miRNAs in the progression of osteoporosis in postmenopausal women. This study aimed to evaluate the association between plasma miRNA-21-5p and miRNA-422a with osteoporosis in postmenopausal women.
METHODS
This cross-sectional comparative study was performed on 126 randomly selected postmenopausal women aged 50-65, including 65 osteoporotic and 61 normal-bone mineral density (BMD) women. miRNA-21 and miRNA-422a were identified using qRT-PCR in these women. BMD was evaluated by the dual-energy X-ray absorptiometry method. A binary logistic regression model adjusted for confounders was used to evaluate the associations between plasma miRNAs' expression levels and osteoporosis. The Area Under Curve (AUC) was calculated to differentiate low BMD in the postmenopausal period using Receiver-Operator Characteristic (ROC) curves.
RESULTS
miRNA-21 and miRNA-422a were significantly up-regulated in osteoporotic compared to non-osteoporotic postmenopausal women. The expression levels of miRNA-21 and miRNA-422a indicated a significant reverse correlation with both lumbar spine and femoral neck density. After adjusting the confounders, the likelihood of osteoporosis in the postmenopausal women with under the median plasma levels of miRNA-21 (OR = 0.025; 95% CI: 0.003 to 0.198, p<0.001) and miRNA-422a (OR = 0.037; 95% CI: 0.007 to 0.211, p<0.001) was significantly less than the women with the levels above the median. There were significant inverse correlations between miRNA-21 (p<0.001, r = -0.511) and miRNA-422a (p<0.001, r = -0.682) with BMD-lumbar spine as well as an inverse correlation between miRNA-21(p<0.001, r = -0.374) and miRNA-422a (p<0.001, r = -0.602) with BMD-femoral neck. The AUC (95%CI) for miRNA-21 and miRNA-422a was 0.84 (0.77 to 0.91) and 0.98 (0.96 to 0.99), respectively. ROC analysis illustrated that sensitivity and specificity values were 83.1% and 74%, respectively, for miRNA-21 at the cut-off point of 3.38. Also, at the cut-off point of 2.86, a sensitivity of 94% as well as a specificity of 89% was determined for miRNA-422a.
CONCLUSIONS
This study indicated that the odds of osteoporosis in postmenopausal women increased with the higher expression of plasma miRNA-21 and miRNA-422a.
Identifiants
pubmed: 37851645
doi: 10.1371/journal.pone.0287458
pii: PONE-D-22-34068
pmc: PMC10584188
doi:
Substances chimiques
MicroRNAs
0
MIRN21 microRNA, human
0
MIRN422 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0287458Informations de copyright
Copyright: © 2023 Mohammadisima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Calcif Tissue Int. 2015 Nov;97(5):495-505
pubmed: 26163235
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
J Clin Densitom. 2013 Oct-Dec;16(4):570-8
pubmed: 23452870
Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6221-6229
pubmed: 30338786
Biomed Pharmacother. 2018 Aug;104:832-840
pubmed: 29566993
PLoS One. 2014 May 12;9(5):e97098
pubmed: 24820117
Eur Urol Focus. 2018 Dec;4(6):825-833
pubmed: 28753866
Int J Mol Sci. 2020 Jan 21;21(3):
pubmed: 31973111
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
J Cell Biochem. 2013 Jun;114(6):1217-22
pubmed: 23238785
Cells. 2020 Feb 19;9(2):
pubmed: 32093031
J Epidemiol. 2010;20(2):150-8
pubmed: 20154450
Stem Cell Res Ther. 2019 Feb 22;10(1):65
pubmed: 30795815
Oncotarget. 2017 Jun 27;8(26):42173-42188
pubmed: 28178679
Int J Mol Sci. 2020 Sep 21;21(18):
pubmed: 32967246
J Cell Physiol. 2018 Dec;233(12):9191-9208
pubmed: 30078225
Ther Clin Risk Manag. 2018 Nov 06;14:2029-2049
pubmed: 30464484
Blood. 2011 Mar 31;117(13):3648-57
pubmed: 21273303
PLoS One. 2011;6(7):e22586
pubmed: 21799909
Eur J Endocrinol. 2017 Feb;176(2):169-176
pubmed: 27836951
Nat Rev Dis Primers. 2016 Sep 29;2:16069
pubmed: 27681935
Mol Cell Biochem. 2015 Jul;405(1-2):125-33
pubmed: 25893734
Mol Med Rep. 2015 Jul;12(1):1561-7
pubmed: 25815684
Clin Exp Pharmacol Physiol. 2020 Jul;47(7):1283-1290
pubmed: 32012318
Cancer Biol Ther. 2018 May 4;19(5):436-444
pubmed: 29509055
J Clin Invest. 2005 Dec;115(12):3318-25
pubmed: 16322775
Mol Med Rep. 2020 Mar;21(3):1125-1132
pubmed: 32016444
Biol Methods Protoc. 2019 Jun 25;4(1):bpz006
pubmed: 32395624
J Bone Miner Res. 2014 Aug;29(8):1718-28
pubmed: 24431276
Acta Med Indones. 2019 Jul;51(3):245-252
pubmed: 31699948
PLoS One. 2012;7(4):e34641
pubmed: 22506038
Biochem Biophys Res Commun. 2017 Nov 18;493(2):928-933
pubmed: 28943430
J Orthop Res. 2015 Jul;33(7):957-64
pubmed: 25728838
Public Health Nutr. 2014 Aug;17(8):1689-96
pubmed: 23941862
Biosci Rep. 2019 May 14;39(5):
pubmed: 31023966
Biomarkers. 2014 Nov;19(7):553-6
pubmed: 25231354
Mol Ther Nucleic Acids. 2020 Jun 5;20:409-420
pubmed: 32244168
EMBO J. 2008 Feb 6;27(3):471-81
pubmed: 18256698